Talazoparib dosing may resume at the next lower dose level (e.g., from 1.0 mg/day to 0.75 mg/day, 0.75 mg/day to 0.5 mg/day) when toxicity resolves to grade 1 or returns to baseline. a Grade 3 nonhematologic toxicity (other than abnormal liver tests): Daily dosing must be held for grade 3 AEs considered related to talazoparib.
Supportive care should be implemented as appropriate (e.g., antiemetics, antidiarrheal agents).
Talazoparib dosing may resume at the next lower dose level (e.g., from 1.0 mg/day to 0.75 mg/day, 0.75 mg/day to 0.5 mg/day to 0.25 mg/day) when toxicity resolves to grade 1 or returns to baseline.
Grade 3 hematologic toxicity: Daily dosing must be held for grade 3 laboratory abnormalities known to be associated with talazoparib.
Supportive care should be implemented as appropriate (e.g., growth factor support, blood products).
Talazoparib dosing may resume at the next lower dose level when toxicity resolves to grade 1 or would meet the eligibility criteria. a,b Grade 4 toxicity: Daily dosing should be stopped.
Talazoparib may resume at a lower dose level (1-2 lower dose level decrease) with the approval of the medical monitor when toxicity resolves to grade 1 or returns to baseline. a Grade 4 nonhematologic toxicity (other than abnormal liver tests): Daily dosing must be held for grade 4 AEs (regardless of relationship to talazoparib).
Supportive care should be implemented as appropriate (e.g., antiemetics, antidiarrheal agents). Talazoparib may resume at a lower dose level (1-2 dose level decrease) when toxicity resolves to grade 1 or returns to baseline.
Grade 4 hematologic toxicity: Daily dosing must be held for grade 4 abnormal laboratory values (regardless of relationship to talazoparib).
Talazoparib may resume but must be at a lower dose level when toxicity resolves to grade 1 or would meet the eligibility criteria a,b ; this should be a 1-2 dose level decrease per Investigator discretion.
*PCT dosing and dose modifications followed local practice/prescribing guidelines. a For the most common hematologic AE (anemia), initial EMBRACA protocol requirements after a grade ≥3 anemia AE (hemoglobin <8 g/dL) required that the talazoparib dose be interrupted until hemoglobin levels recovered to grade 1 (≥10 g/dL) or baseline before resuming talazoparib at the next lower dose level, whereas EMBRACA eligibility criteria were permitted with a hemoglobin value ≥9 g/dL. EMBRACA protocol was later amended as follows: in the case of a grade ≥3 anemia (<8 g/dL), hemoglobin levels must return to grade 1 or meet study inclusion criteria (≥ 9 g/dL) before talazoparib could resume at the next lower dose level. This requirement potentially facilitated investigators to provide PRBC transfusions and/or anti-anemic use at a higher hemoglobin level than recommended by current clinical practice/international clinical guidelines (1, 2 Table S2 . Dose modification and management from US prescribing information
Adverse reactions
Withhold talazoparib until levels resolve
Resume talazoparib
Hemoglobin <8 g/dL ≥9 g/dL Resume talazoparib at a reduced dose Platelet count <50 × 10 9 /L ≥75 × 10 9 /L Neutrophil count <1000 × 10 6 /L ≥1500 × 10 6 /L Nonhematologic grade 3 or 4 Grade ≤1
Consider resuming talazoparib at a reduced dose or discontinue
Supportive Medications
Supportive medications could be provided prophylactically or therapeutically at the discretion of the investigator. Granulocyte colony-stimulating factor was allowed only in the rescue setting. Allowed medications included, but were not limited to, antiemetics (e.g., dexamethasone, metoclopramide, ondansetron, aprepitant), antidiarrheals (e.g., loperamide hydrochloride), and appetite stimulants (e.g., megestrol acetate). Bisphosphonates and denosumab were allowed for the treatment or prophylaxis of bone metastases per local standards of care.
Gonadotropin-releasing hormones were permitted to maintain ovarian suppression in patients with hormone receptor-positive breast cancer.
Patient-Reported Outcomes (PRO) Analyses
Patient-reported outcome analyses were performed in 2 subgroups of patients with 
Health Resource Utilization (HRU) Analyses

Serious Adverse Event-Associated Hospitalization
Only serious adverse event (SAE)-associated hospitalization was recorded in EMBRACA and assessed a priori. An SAE was defined as any AE that resulted in death, was considered to be life-threatening or medically important, resulted in hospitalization or prolongation of existing hospitalization, or resulted in persistent or clinically significant disability or incapacity or a congenital anomaly or birth defect.
SAE-associated hospitalization rate was calculated using the following equation:
Due to data limitations, the SAE-associated hospitalization rates do not account for the length of hospitalization for each patient. Other types of hospitalizations are also not captured in EMBRACA. a Total time from the start date of treatment-emergent (TE) period to the start date of first SAE-associated hospitalization or the end date of TE period, whichever is earlier.
Supportive Care Medication Utilization
The following categories of supportive care medication (SCM) were selected a priori and assessed in this study: 
Methods for Landmark Analysis
Landmark analyses using the Kaplan-Meier method were conducted to assess the impact of talazoparib dose reduction, regardless of cause, on progression-free survival (PFS) in patients. Three landmarks (12, 18 and 24 weeks) were used.
Patients whose PFS time was shorter than the landmarks were excluded. Patients whose talazoparib dose was reduced before a landmark were assigned to the dose reduction group. Those without dose reduction or those with a dose reduction after the landmark were assigned to the group without a dose reduction. PFS time was calculated from landmark. 
AEs in Patients ≥65 Years of Age
The proportion of elderly patients aged ≥65 years was small in both treatment arms, with 27 patients (9.4%) receiving talazoparib and 8 patients (6.3%) receiving PCT.
The overall incidence of AEs was generally similar across treatment arms and age Table S5 ). Nonhematologic adverse events (nausea, vomiting) are based on a single preferred term, whereas fatigue is inclusive of fatigue/asthenia. Abbreviation: TEAE, treatment-emergent adverse event.
Dose Reductions
AEs associated with dose reduction in ≥2% of patients are presented by decreasing frequency (Table S6 ). In those receiving talazoparib, the most frequently reported After dose reduction, frequency and grades of AEs decreased ( Figure S4 ). Abdominal pain 0 (0.0) 3 (2.4) *To provide a more accurate assessment of AEs associated with dose reduction, AEs leading to dose interruption or dose reduction were cross-referenced by the medical reviewer with the study drug dosing records. If a dose interruption was followed by a dose reduction, the most likely preceding AE was identified as the cause of the dose reduction. Abbreviations: AE, adverse event; TEAE, treatment-emergent AE.
Dose Modifications Associated With AEs
Dose modifications associated with AEs based on dosing record for talazoparib are presented in Table S7 . A total of 52.1% of patients had ≥1 dose reduction associated with AEs. The median time to the first talazoparib dose reduction was 19.3 weeks (95% CI: 17.1, 30.9). Dosing interruptions associated with AEs were reported for 172 of 286 patients (60.1%) in the talazoparib arm (Table S7 ). The median duration of each talazoparib dosing interruption was 8.0 days (range, 1-50) and the median total duration of dosing interruptions was 18.5 days (range, 1-96). 
Landmark Analysis of Talazoparib Dose Reductions
Landmark analyses showed a trend towards a slightly less favorable PFS for patients that had a dose reduction versus those who did not ( Figure S5A , B, and C, respectively). Landmark analyses have lower efficiency to evaluate the effect of dose reductions on PFS than the Cox Models (Table 3 ) because a landmark analysis excludes patients and events that occur before the landmark, as well as not reflecting patients who may switch groups after the landmark. Nonetheless, both analyses cannot adjust for the lack of randomization, and therefore we do not know if dose reduction itself leads to worse PFS or if it is just a marker for patients with worse prognosis and hence shorter PFS. None of the PCT-treated patients had platelet transfusion during EMBRACA. c Of note, initial study protocol requirements for hemoglobin levels to recover to grade 1 (≥ 10 g/dL) or baseline following dose interruption due to an anaemia event before resuming talazoparib/PCT were amended during the trial, whereas study entry was permitted with a hemoglobin value ≥ 9 g/dL.3 Prior to the protocol amendment, these requirements may have encouraged RBC transfusion and/or antianaemic use in order to resume talazoparib/PCT, more than would be expected in routine clinical practice. d Filgrastim, pegfilgrastim, granulocyte colony-stimulating factor, sargramostim, lenograstim. Abbreviations: PCT, physician's choice chemotherapy; PRBC, packed red blood cells; SD, standard deviation.
